3/28
07:09 am
ppbt
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 [Yahoo! Finance]
Medium
Report
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 [Yahoo! Finance]
3/28
07:00 am
ppbt
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Medium
Report
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
3/14
07:52 am
ppbt
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology [Yahoo! Finance]
Medium
Report
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology [Yahoo! Finance]
3/14
07:30 am
ppbt
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Medium
Report
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
3/5
01:01 pm
ppbt
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Neutral
Report
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/5
08:10 am
ppbt
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
3/5
07:55 am
ppbt
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
Medium
Report
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
2/27
01:08 pm
ppbt
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
2/27
07:03 am
ppbt
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 [Yahoo! Finance]
Medium
Report
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 [Yahoo! Finance]
2/27
07:00 am
ppbt
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
Medium
Report
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
2/13
07:11 am
ppbt
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial [Yahoo! Finance]
High
Report
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial [Yahoo! Finance]
2/13
07:00 am
ppbt
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Medium
Report
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
2/1
07:37 am
ppbt
Purple Biotech Reaches Recommended Phase 2 Dose for NT219 [Yahoo! Finance]
Medium
Report
Purple Biotech Reaches Recommended Phase 2 Dose for NT219 [Yahoo! Finance]
2/1
07:30 am
ppbt
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
High
Report
Purple Biotech Reaches Recommended Phase 2 Dose for NT219